GlassScriptPhysician profile
David D Bot
NPI 1578789335
$7,595.96
in general payments reported to CMS, 2019-2025
26 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $741 · 2021: $1,296 · 2022: $1,392 · 2023: $1,004 · 2024: $826 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,974 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,973.62 |
| Education | $235.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,206.85 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $1,030.30 | 2019-2025 | Invega Sustenna, Spravato |
| Sunovion Pharmaceuticals INC. | $979.00 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $687.71 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $539.81 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $532.75 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $505.61 | 2021-2025 | Vraylar |
| Allergan, INC. | $412.77 | 2019-2020 | |
| Alkermes, INC. | $328.90 | 2020-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $290.85 | 2022-2025 | Auvelity |
| Lundbeck LLC | $282.86 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $156.26 | 2019-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $113.39 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $87.85 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $84.85 | 2025 | Cobenfy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $69.07 | 2021-2022 | |
| Alfasigma USA, INC. | $52.45 | 2020 | |
| Eisai INC. | $44.78 | 2020 | |
| Idorsia Pharmaceuticals US INC | $44.75 | 2024 | Quviviq |
| Indivior INC. | $40.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.62 | 2019 | |
| Collegium Pharmaceutical, INC. | $20.03 | 2025 | Jornay Pm |
| Shire North American Group INC | $18.83 | 2019 | |
| Corium, LLC | $16.81 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.99 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.